<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823953</url>
  </required_header>
  <id_info>
    <org_study_id>DMC0107</org_study_id>
    <nct_id>NCT00823953</nct_id>
  </id_info>
  <brief_title>Glycemic Response to Momordica Charantia in Type 2 Diabetes</brief_title>
  <official_title>The Effect of Momordica Charantia on Glycemic Control and Insulin Resistance in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Hospital, Lahore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Punjab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Services Hospital, Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a common disease which has been treated by traditional medicines for centuries&#xD;
      before modern medicine became available. A very common remedy for Diabetes Mellitus in&#xD;
      different cultures is momordica charantia (karela or Bitter gourd). The use of alternative&#xD;
      medicine is common among Pakistani population. This study was planned to find out the effect&#xD;
      of administering freeze dried powder of momordica charantia for three weeks on the glycemic&#xD;
      profile and insulin resistance of treatment naiive patients with mild Type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Momordica charantia is a commonly consumed vegetable, which has formed a part of&#xD;
      subcontinental diet since centuries. It has been traditionally used to treat diabetes across&#xD;
      three continents, and its glycemic effect has been investigated in a few unblinded trials,&#xD;
      but so far no properly designed double blind investigation of its action on insulin&#xD;
      resistance has not been carried out. In this study, a randomised placebo controlled&#xD;
      double-blind trial will be carried out on mild type 2 diabetic patients, to study the effect&#xD;
      of escalating doses of Momordica charantia administered in the form of capsules for the trial&#xD;
      phase of three weeks, on glycemic control and parameters of insulin resistance in type 2&#xD;
      diabetes. Among the parameters to be tested will be glucose indices and lipid profile and&#xD;
      insulin levels. The effect of Momordica charantia administration on insulin resistance will&#xD;
      be assessed using HOMA-IR model and/ or the hyperinsulinemic, euglycemic clamp. The selection&#xD;
      of patients with mild hyperglycemia will be done to offset the glucose spill-off effect which&#xD;
      occurs beyond the real threshold, and makes the glucose tolerance curve non-linear beyond&#xD;
      this level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IP could not be made available in sufficient quantity for the expected enrollment&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum fructosamine at end of trial phase in each of the groups</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of major adverse effects (e.g. intractable vomiting, jaundice, allergic reactions or other effects requiring cessation of therapy and breaking of study code)</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1[7-36] in each group at the end of trial phase</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FBG at end of trial phase in each of the groups</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR in each of the two groups at end of trial phase</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Momordica charantia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.&#xD;
The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Momordica charantia</intervention_name>
    <description>escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.</description>
    <arm_group_label>Momordica charantia</arm_group_label>
    <other_name>Bitter Melon Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>starch powder</intervention_name>
    <description>The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult Type 2 diabetics with mild degree of hyperglycemia (FBG &gt;126&lt;200 mg/dl)&#xD;
&#xD;
          2. Absence of serious co-morbid conditions&#xD;
&#xD;
          3. Patients agreeing to participate in this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetics&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Paediatric age group&#xD;
&#xD;
          4. Patients known to be allergic to Momordica charantia&#xD;
&#xD;
          5. Serious cardio-respiratory illness, previous myocardial infarction, angina pectoris,&#xD;
             heart failure, uncontrolled hypertension â‰¥ stage 2, COPD, asthma, active pulmonary&#xD;
             tuberculosis&#xD;
&#xD;
          6. Significant hepatic impairment: ALT &gt;60, Bilirubin &gt;2 mg/dl&#xD;
&#xD;
          7. Significant renal impairment: S/creatinine &gt;1.5 mg/dl, albuminuria &gt; 1+&#xD;
&#xD;
          8. Patients with conditions likely to interfere with the absorption of the trial therapy:&#xD;
             malabsorption, chronic diarrhoea, intestinal resection, blind loop syndrome&#xD;
&#xD;
          9. Patients withholding consent&#xD;
&#xD;
         10. Patients, both male and female, desiring pregnancy during the trial phase.&#xD;
&#xD;
         11. Secondary causes of diabetes&#xD;
&#xD;
         12. Patients using drugs influencing glucose metabolism: steroids, hormonal contraception,&#xD;
             menopausal HRT , diazoxide, phenytoin, colchicine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khadija I Khawaja, MBBS,FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Services Hospital, Lahore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Services Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://www.rain-tree.com/bitmelon.htm</url>
    <description>Database File for Momordica charantia</description>
  </link>
  <reference>
    <citation>Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res Clin Pract. 1998 Jun;40(3):145-51.</citation>
    <PMID>9716917</PMID>
  </reference>
  <reference>
    <citation>Ahmed I, Lakhani MS, Gillett M, John A, Raza H. Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract. 2001 Mar;51(3):155-61.</citation>
    <PMID>11269887</PMID>
  </reference>
  <reference>
    <citation>Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol. 2007 Jun;60(6):554-9. Epub 2006 Nov 13.</citation>
    <PMID>17493509</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>June 9, 2012</last_update_submitted>
  <last_update_submitted_qc>June 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Services Hospital, Lahore</investigator_affiliation>
    <investigator_full_name>Khadija Irfan Khawaja</investigator_full_name>
    <investigator_title>Assistant Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>diabetes type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

